tirzepatide cardiovascular outcomes linked to lower risk for death, adverse CV and kidney vs. GLP-1s tirzepatide cardiovascular outcomes study Effects

As a GLP-1 receptor agonist, tirzepatide may slow gastric emptying, which can prolong the feeling of fullness after meals and reduce appetite

Neither lane is better than the other

Our individualized approach at Ivm Health allows your care team to monitor your progress and adjust your treatment plan as needed

Researchers at wellness clinics who administer this combination report that patients experience enhanced results compared to tirzepatide alone, particularly in stubborn fat deposits that resist GLP-1 therapy

Maintenance dose: 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults